Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon.

Abstract : Digital skin vasoconstriction on local cooling is exaggerated in primary Raynaud's phenomenon (RP) as compared with controls. A significant part of such vasoconstriction relies on the inhibition of the nitric oxide (NO) pathway. We tested the effect of the phosphodiesterase 5 (PDE5) inhibitor sildenafil, which potentiates the effect of NO, on skin blood flow. We recruited 15 patients with primary RP, performing local cooling without sildenafil (day 1), after a single oral dose of 50 mg (day 2), and after a dose of 100 mg (day 3). Skin blood flow, skin temperature, and arterial pressure were recorded, and data were expressed as cutaneous vascular conductance (CVC). Sildenafil at 100 mg, but not 50 mg, significantly lessened the cooling-induced decrease in CVC. It also increased resting CVC and skin temperature. These data suggest that 100 mg sildenafil improves digital skin perfusion during local cooling in primary RP. The benefit of sildenafil "as required" should be confirmed in a randomized, controlled trial.
Type de document :
Article dans une revue
Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2012, 91 (5), pp.813-9. 〈10.1038/clpt.2011.302〉
Liste complète des métadonnées

Littérature citée [1 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00767054
Contributeur : Matthieu Roustit <>
Soumis le : mercredi 19 décembre 2012 - 14:02:26
Dernière modification le : jeudi 30 novembre 2017 - 09:16:50
Document(s) archivé(s) le : mercredi 20 mars 2013 - 11:36:35

Fichiers

inserm-00767054_edited.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

UGA

Citation

Matthieu Roustit, Marcin Hellmann, Claire Cracowski, Sophie Blaise, Jean-Luc Cracowski. Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon.. Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2012, 91 (5), pp.813-9. 〈10.1038/clpt.2011.302〉. 〈inserm-00767054〉

Partager

Métriques

Consultations de la notice

228

Téléchargements de fichiers

1403